What Forteo Treats
Forteo (teriparatide) is a synthetic form of parathyroid hormone used to treat osteoporosis in postmenopausal women at high risk for fracture, men with primary or hypogonadal osteoporosis at high fracture risk, and glucocorticoid-induced osteoporosis in men and women at high risk.[1]
How Forteo Works
It stimulates new bone formation by mimicking the body's natural parathyroid hormone, which activates osteoblasts (bone-building cells). Patients self-administer daily subcutaneous injections via a prefilled pen for up to 2 years maximum.[1]
Who Qualifies for Forteo
Prescribed for severe cases where other treatments fail, such as those with very low bone mineral density (T-score ≤ -2.5) or prior fragility fractures. Not for routine osteoporosis or patients under 18.[1]
Common Side Effects Patients Report
Dizziness, leg cramps, nausea, joint pain, and injection site reactions occur in >5% of users. Rare risks include osteosarcoma (bone cancer) based on animal studies, so it's limited to 2 years and avoided in those with bone metastases or radiation history.[1]
How Forteo Compares to Other Osteoporosis Drugs
Unlike bisphosphonates (e.g., Fosamax) that slow bone breakdown, Forteo builds bone. Often followed by an antiresorptive like denosumab. Studies show it reduces vertebral fractures by 65% vs. placebo.[1]
Treatment Duration and Follow-Up
Maximum 24 months due to osteosarcoma risk; post-Forteo, switch to maintenance therapy. Bone density monitored via DEXA scans.[1]
Who Makes Forteo and Pricing
Eli Lilly manufactures it. A 28-day supply costs $3,000-$4,000 without insurance; patient assistance programs available.[1]
Patent Status and Generics
Key U.S. patents expired in 2019-2022, but no generics approved yet due to device complexity. Check DrugPatentWatch.com for litigation updates.[2]
[1] Forteo Prescribing Information, Eli Lilly and Company (FDA-approved label).
[2] DrugPatentWatch.com - Forteo patents and exclusivity.